Shares of Catalent Inc (NYSE:CTLT) ended Monday session in red amid volatile trading. The shares closed down -0.49 points or -1.84% at $26.21 with 1.19 million shares getting traded. Post opening the session at $26.45, the shares hit an intraday low of $26.11 and an intraday high of $26.67 and the price vacillated in this range throughout the day. The company has a market cap of $3.28 billion and the numbers of outstanding shares have been calculated to be 124.74 million shares.
Catalent Inc (CTLT) on September 13, 2016 announced an agreement for Catalent, through its wholly owned subsidiary, Catalent Pharma Solutions, Inc., to acquire Pharmatek Laboratories, Inc., a West Coast, U.S.-based specialist in drug development and clinical manufacturing. The acquisition will add extensive early-phase drug development capabilities from discovery to clinic, bring spray drying into Catalent’s portfolio of drug formulation and delivery technologies, and expand Catalent’s capability for handling highly potent compounds. The addition of spray drying will also provide Catalent customers with a comprehensive suite of bioavailability enhancement solutions, while complementing and expanding Catalent’s OptiForm® Solution Suite platform, a science-driven parallel screening approach to identify the optimal formulation pathway for poorly soluble compounds. No financial details have been disclosed.
Shares of VIVUS, Inc. (NASDAQ:VVUS) ended Monday session in green amid volatile trading. The shares closed up +0.11 points or 9.73% at $1.24 with 1.18 million shares getting traded. Post opening the session at $1.13, the shares hit an intraday low of $1.11 and an intraday high of $1.25 and the price vacillated in this range throughout the day. The company has a market cap of $135.17 million and the numbers of outstanding shares have been calculated to be 104.18 million shares.
VIVUS, Inc. (VVUS) on August 29, 2016 announced an extension of the termination date of the license agreement between Auxilium and VIVUS for STENDRA® (avanafil) U.S. and Canadian commercial rights through September 30, 2016.
“We have been working closely with Auxilium to ensure a smooth transition of STENDRA back to VIVUS,” said Seth H. Z. Fischer, VIVUS Chief Executive Officer. “Through this process, we have determined that a handoff of STENDRA at the end of a calendar quarter provides the most efficient cut-off date for our internal processes, customers and vendors. We are concurrently preparing to commercialize STENDRA in the U.S. while maintaining discussions to license or sell STENDRA’s U.S. commercialization rights.”